Elinzanetant
Non-hormonal treatment of menopausal vasomotor symptoms (hot flashes)
- CAS No.
- 929046-33-3
- Indication Class
- Urology / Women's Health
- Patent Expiry
- To be assessed
- Therapeutic Area
- Women's Health
- Target / Mechanism
- TACR1·TACR3
- Labeled Purity
- 99%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- 9 key intermediates available
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higher| Intermediate | CAS | Shared | Action |
|---|---|---|---|
| ((7S)-octahydropyrazino[2,1-c][1,4]oxazin-7-yl)methanol | 929047-29-0 | — | |
| (7S,9aS)-7-((Benzyloxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine dioxalate salt | 1268364-46-0 | — | |
| 2-(3,5-bis-trifluoromethylphenyl)-2-methyl-propionyl chloride | 289686-69-7 | — | |
| 2-(3,5-bis(trifluoroMethyl)phenyl)-2-Methyl propanoic acid | 289686-70-0 | — | |
| 3-Morpholinemethanol, 4-(phenylmethyl)-, hydrochloride | 916483-67-5 | — | |
| 4-Boc-3-morpholinecarboxylic Acid | 212650-43-6 | — | |
| 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine hydrochloride | 2642577-31-7 | — | |
| N-[6-Chloro-4-(4-fluoro-2-methylp henyl)-3-pyridinyl]-N,a,a-trimethy | 825643-73-0 | — | |
| N-Boc-O-Benzyl-D-serine | 47173-80-8 | — |
Listing Logic · Why It's Worth Listing
A dual-receptor antagonist expected to further improve efficacy and sleep versus first-generation NK3 agents; a validated segment with large demand.
Women's Health · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
9 key intermediates available; scale-up and cost control manageable
Product Description
Elinzanetant is an oral dual neurokinin receptor antagonist that simultaneously blocks NK1 and NK3 receptors. The drug is primarily being studied for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with menopause.
Supply source: Unibest · Elinzanetant, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.